Managing CDK4/6 Inhibitor Toxicities in Breast Cancer

Effective management of adverse events and addressing barriers to care are critical to optimizing outcomes and maintaining quality of life for patients receiving CDK4/6 inhibitors. In this episode, CANCER BUZZ speaks with Julia Lea Ziegengeist, PharmD, BCOP, clinical pharmacist coordinator in solid tumor oncology at Atrium Health Levine Cancer Institute about proactive, team-based strategies to identify, monitor, and manage treatment-related toxicities in patients with early-stage and metastatic HR-positive, HER2-negative breast cancer. Dr. Ziegengeist sheds light on the patient journey, the roles of various multidisciplinary care team members, and useful resources for language and literacy barriers.

"I think the biggest thing that is specific to CDK4/6 inhibitors is... eligibility criteria and when we're using the drugs in what setting, having those monitoring protocols and getting that multidisciplinary collaboration is really key." – Julia Lea Ziegengeist, PharmD, BCOP

Julia Lea Ziegengeist, PharmD, BCOP

Clinical Pharmacist Coordinator, Solid Tumor Oncology 

Levine Cancer Institute 

Atrium Health 

Charlotte, NC 

Resources:

ACCC Resource: CDK4/6 Inhibitors Management

ACCC CDK4/6 Inhibitors Infographic